In short, HDAC has a key role in the pathogenesis of PAH, and HDAC inhibitors have been demonstrated as potential pharmacologic agents to improve vascular and RV remodeling, including reduced proliferation, induced apoptosis, and suppressed inflammation in induced PAH using experimental animal or cell culture models. The gene discussed is HDAC9; the disease is pulmonary arterial hypertension.